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Abstract
Introduction: Diabetes mellitus is a key predictor of mortality in rheumatoid arthritis (RA) patients. Both RA and
diabetes increase the risk of cardiovascular disease (CVD), yet understanding of how comorbid RA impacts the
receipt of guideline-based diabetes care is limited. The purpose of this study was to examine how the presence of
RA affected hemoglobin A1C (A1c) and lipid measurement in older adults with diabetes.
Methods: Using a retrospective cohort approach, we identified beneficiaries ≥65 years old with diabetes from a
5% random national sample of 2004 to 2005 Medicare patients (N = 256,331), then examined whether these
patients had comorbid RA and whether they received guideline recommended A1c and lipid testing in 2006.
Multivariate logistic regression was used to examine the effect of RA on receiving guideline recommended testing,
adjusting for baseline sociodemographics, comorbidities and health care utilization.
Results: Two percent of diabetes patients had comorbid RA (N = 5,572). Diabetes patients with comorbid RA were
more likely than those without RA to have baseline cardiovascular disease (such as 17% more congestive heart
failure), diabetes-related complications including kidney disease (19% higher), lower extremity ulcers (77% higher)
and peripheral vascular disease (32% higher). In adjusted models, diabetes patients with RA were less likely to
receive recommended A1c testing (odds ratio (OR) 0.84, CI 0.80 to 0.89) than those without RA, but were slightly
more likely to receive lipid testing (OR 1.08, CI 1.01 to 1.16).
Conclusions: In older adults with diabetes, the presence of comorbid RA predicted lower rates of A1c testing but
slightly improved lipid testing. Future research should examine strategies to improve A1c testing in patients with
diabetes and RA, in light of increased CVD and microvascular risks in patients with both conditions.
Introduction
The Centers for Disease Control and Prevention esti-
mate that >26% of adults over 65 have diabetes mellitus
(DM), and reports note that diabetes is a key mortality
predictor in patients with rheumatoid arthritis (RA)
[1-3]. Both RA and DM increase cardiovascular disease
(CVD) risk; thus, the question of how comorbid RA
impacts diabetes care merits consideration, but has
received little prior attention. It is generally accepted
that diabetes control, monitored by American Diabetes
Association recommended annual cholesterol and
biannual hemoglobin A1C (A1c) testing [4], reduces
macro- and microvascular complications, respectively
[5-7]. At the same time, the European League Against
Rheumatism (EULAR) recommends “annual cardiovas-
cular risk assessment” [8] for RA patients, which
although not explicitly stated, would likely include
screening and monitoring traditional cardiac risks, such
as hyperlipidemia. Still, a 2011 report cited that only
32% of general practitioners recognized RA as an inde-
pendent risk factor for CVD [9], despite growing evi-
dence regarding the heightened risk of CVD associated
with RA [10,11].
The goal of this study was to examine the impact of RA
upon guideline-recommended diabetes care, including
biannual A1c and annual low-density lipoprotein (LDL)
cholesterol testing, in a cohort of Medicare patients with
diabetes. When examining the impact of comorbidity on
care for a given chronic condition, some authors predict
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less preventive care and guideline adherence in patients
with greater comorbidity[12], and others predict more
care due to increased visits and provider contacts [13]. A
recent model by Piette and Kerr shifts this concept,
arguing that rather than the amount of comorbidity, it is
the nature of the specific comorbidities and their rela-
tionship to the guideline-based tasks that predicts care
delivery [14,15]. The model predicts higher quality when
the goals of care for two conditions, such as RA and dia-
betes, align or are “concordant”, and lower quality when
the goals of care for two conditions are “discordant.” We
hypothesized that providers would consider glycemic
control unrelated to the management of RA (goals are
discordant), and that active, symptomatic RA disease
would in turn lessen attention to diabetes A1c testing.
This predicts decreased A1c testing in diabetes patients
when RA is present. In contrast, given the heightened
cardiovascular risks associated with both RA and dia-
betes, we hypothesized that lipid management would be
a “concordant” preventive goal in patients with both con-
ditions, predicting increased lipid testing in diabetes
patients when RA was also present.
Materials and methods
Setting and participants
In this retrospective cohort study, beneficiaries aged 65
and older with diabetes who were continuously enrolled
and alive from 2004 to 2006 were identified from a 5%
random US Medicare sample, the Medicare Chronic Con-
dition Warehouse dataset [16][17]. Patients were deter-
mined to have diabetes using a validated algorithm
requiring at least one inpatient or skilled nursing facility
claim or more than one professional service claim in 24
months for the following International Classification of
Diseases, 9th Revision (ICD-9) codes: 250.xx, 357.2, 362.0x,
366.41, or 648.0x [18].
Study design
Among this cohort of Medicare beneficiaries with dia-
betes, patients were classified as having or not having RA
(see Figure 1) based on the presence or absence of two or
more RA ICD-9 codes (714.0 to 714.33) on inpatient or
outpatient claims at least 2 months apart in 24 months,
using modifications of a previously validated algorithm
[19,20]. Both the diabetes and RA diagnostic definitions
were applied to the 2004 to 2005 period to establish
these diagnoses prior to assessment of 2006 diabetes care
measures.
Enrollment and claims data (2004 to 2006) were
extracted for all diabetes patients. The Medicare denomi-
nator file was used to exclude beneficiaries without con-
tinuous Medicare Part A or B coverage or those enrolled
in a Medicare health maintenance organization or rail-
road benefits. We also excluded patients without any
outpatient encounters during 2004 to 2006 given the lim-
ited opportunity for disease monitoring in such cases.
Deaths were captured from the Medicare demographic
and enrollment file. The Institutional Review Board at
the University of Wisconsin approved this study with a
waiver of consent.
Based upon the validated diabetes diagnosis algorithm
indicating eligibility for diabetes care metrics in 2006, we
identified 256,331 patients with diabetes. Among them,
we identified 5,572 (2.2%) older adults with comorbid RA
and diabetes.
Variables
All variables were obtained from Medicare data. Depen-
dent variables included receiving lipid testing (that is,
LDL cholesterol testing) and at least two A1c tests in
2006 as assessed by searching carrier, outpatient or inpa-
tient facility claims per prior reports [21,22]. The main
explanatory variable was the presence or absence of RA
among patients with diabetes.
The Chronic Condition Warehouse contains flags cre-
ated using numerous established algorithms applied bian-
nually since 1999 to define 21 chronic diseases [16,23-27].
The Chronic Condition Warehouse 2005 end-of-year indi-
cators were used to denote baseline comorbidities, includ-
ing pre-existing chronic kidney disease, CVD, ischemic
heart disease, myocardial infarction (MI), congestive heart
failure (CHF) or stroke/transient ischemic attack (TIA)
[23-26]. Baseline hyperlipidemia was identified by the pre-
sence of more than one ICD-9 code for the condition
(272.0 to 272.4) in 24 months from 2004 to 2005 [25,28].
Baseline diabetes complications were defined using a vali-
dated algorithm to search for claims through 2005 indicat-
ing the presence of lower extremity ulcers, amputation,
diabetic eye disease including macular edema or retinopa-
thy, and peripheral vascular disease [29].
Individual sociodemographic and clinical characteristics
were included as other potential explanatory variables.
These included baseline (2004) age, sex, race, designation
of ever receiving Medicaid and zip code residence group-
ing using US Department of Agriculture census-based
Rural Urban Commuting Area (RUCA) codes (urban, sub-
urban, large town or small town based upon population
census and commuting flows) [30]. Claims for a gait-assis-
tance device or orthopedic surgery [31,32] during the
study period were used to assess musculoskeletal health in
the absence of validated administrative indicators of RA
severity (code lists available upon request).
Patient risk adjustment was addressed using the Cen-
ters for Medicare and Medicaid Services - Hierarchical
Condition Categories (HCC) community risk score [33].
The HCC approach creates a score for the beneficiary
predicting Medicare expenditures in the subsequent year
based on 3,000 ICD-9 codes gathered from all inpatient
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and outpatient encounters from the prior year (2005) to
assign the beneficiary to 70 specific “condition cate-
gories”, which are clinically and cost similar. In HCC
scoring comorbidity is reflected by allowing a beneficiary
to belong to multiple condition categories. Beneficiary
demographic adjusters are also included (that is, age,
gender, Medicaid status, disabled status) in the creation
of the final HCC score (average score = 1.0, with higher
scores indicating greater risk/complexity).
Measures of utilization included total number of pri-
mary care visits each year and total number of unique
providers from 2004 to 2006, as well as ever being hospi-
talized in 2004 to 2006. We used billing dates within the
carrier file to determine the number of visits. Provider
specialty codes were used to count unique provider totals
and distinguish primary care, rheumatology and non-
rheumatology specialist visits. Primary care provider
(PCP) visits were defined as outpatient encounters with
family medicine or internal medicine physicians, nurse
practitioners or physician assistants [34,35]. Visits and
provider counts with rheumatology and other (non-rheu-
matology) specialists were also assessed.
Statistical analysis
Logistic regression with robust estimates of the variance
was used to analyze the relationship between explanatory
variables and receiving at least two A1c tests or one LDL
test. Next, predicted probabilities, adjusted risk ratios
(ARR), and odds ratios (OR) for testing were calculated
for those with and without comorbid RA . Age, gender,
race/ethnicity, Medicaid buy-in, RUCA category, HCC
quartile, hospitalization during 2004 to 2006, and other
specific comorbidities, including diabetic complications,
hyperlipidemia, chronic kidney disease, CVD, orthopedic
surgery, gait-assistance device, total number of unique
providers seen by quartile and visit frequencies, also were
included within logistic models based upon theoretical
importance.
Yes 
Medicare Diabetes Patients 





DM+ RA n= 5572  Lone DM n= 250759  
Outcomes: 2006 >1 A1c tests? Any LDL test? 
Figure 1 Cohort selection flow diagram for Medicare diabetes patients with and without comorbid RA.
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Analyses were conducted using SAS version 9.1.3
(SAS Institute, Inc., Cary, NC, USA) and Stata version
10.0 (StataCorp, College Station, TX, USA). Adjusted
predicted probabilities were estimated based on the
recycled predictions approach using the Stata margins
command which facilitated ARR calculation. ARR com-
parison was included given methodological benefits of
this approach when interpreting common outcomes like
lipid testing [36]. The recycled predictions approach
predicts the outcome (testing) assuming that everyone
in the dataset was treated as if they first did and then
did not have RA. Confidence intervals were calculated
using the delta method and allowed correlation among
observations (analogous to the robust option) to esti-
mate the logistic regression [37].
We conducted a sensitivity analysis examining the effect
of RA on patients’ receipt of at least one instead of two
A1c tests. There was no change in directionality, statistical
significance or relative magnitude of the main results, and
thus we present the original models described above.
Results
Descriptive characteristics
Table 1 shows characteristics of our final sample of
256,331 Medicare beneficiaries with diabetes by RA sta-
tus. In total, 5,572 (2.2%) of these patients had comorbid
RA (Table 1). Compared to diabetes patients without RA,
those with RA were more likely to be female, receive
Medicaid and live in an urban area. On average, diabetes
patients with comorbid RA saw more total unique provi-
ders over the three-year study period (8.8 ± 5.7 versus
6.3 ± 4.0, P <0.01). Similarly, they had more outpatient
provider visits per year (14.7 ± 9.3 versus 9.6 ± 6.7,
P <0.01), although rheumatology encounters represented
only on average two (± 3.1) of these visits. Diabetes
patients with RA had higher HCC scores (1.55 ± 1.04
versus 0.82 ± 0.80, P <0.01) and were more likely to be
hospitalized or have orthopedic surgery or gait device
history. Patients with comorbid RA also had more CVD,
including 28% more CHF, 15% more ischemic heart dis-
ease and 11% higher stroke/TIA, but did not differ in
rates of baseline MI (P = 0.2).
Effect of RA on baseline diabetes complications
Surprisingly, patients with RA differed from patients with-
out RA with regard to four of five baseline diabetes com-
plications. Specifically, diabetes patients with RA were 19%
more likely to have chronic kidney disease (unadjusted
rate 17.1% compared to 14.4%, P <0.01). Lower extremity
ulcers were 77% more likely in diabetes patients with RA
(13% compared to 7%, P <0.01). Peripheral vascular dis-
ease was 32% more prevalent among diabetes patients
with RA than those without (43% compared to 33%,
P <0.01), as were amputations (0.9% versus 0.6%,
P = 0.05). Diabetic eye disease was the only complication
observed less frequently in RA (14% compared to 16%,
P <0.01).
Diabetes care quality testing performance
Effect of RA
The presence of RA among diabetes patients decreased
the probability of A1c testing, but slightly increased
lipid testing, even after controlling for baseline sociode-
mographic, comorbidity and utilization differences
(Table 2). Before adjustment, 52% of patients with both
diabetes and RA versus 57% without RA received at
least two A1c tests. After adjustment, diabetes patients
with RA were significantly less likely than those without
RA to receive the recommended two A1c tests per year
(OR 0.84, CI 0.80 to 0.89). Unadjusted LDL testing was
similar in both groups (76% with RA versus 77% with-
out), although adjusted models showed that diabetes
patients with RA were slightly more likely to be tested
(OR 1.08, 1.01 to 1.16).
Effects of other comorbidities on testing
Our adjusted model revealed that younger age, female
gender and Caucasian race were all significantly associated
with receiving recommended diabetes testing (data not
shown, see Additional file 1). In addition, the presence of
baseline microvascular complications (Figure 2, panel A)
was associated with receiving recommended A1c testing
(for chronic kidney disease (ARR 1.08 (95% CI 1.07 to
1.09); for lower extremity ulcers ARR 1.03 (1.02 to 1.04);
for amputation ARR 1.05 (1.00 to 1.09); for diabetic eye
disease ARR 1.22 (1.21 to 1.23); for peripheral vascular dis-
ease ARR 1.03 (1.03 to 1.04)). Prevalent CVD burden was
associated with less diabetes testing (Figure 2), although
acute MI, ischemic heart disease and peripheral vascular
and eye disease predicted equivalent or more lipid testing.
As expected, measures of worse overall health (hospitaliza-
tion and highest quartile HCC) were associated with less
guideline-recommended diabetes screening, and ambula-
tory difficulty reflected by use of a gait-assistance device
was associated with less diabetes screening (results not
shown, see Additional file 1).
Discussion
In this large national cohort study of Medicare diabetes
patients with and without RA, the comorbid presence of
RA predicted lower rates of A1c testing, but slightly
improved lipid testing, and was associated with higher
baseline CVD and diabetes microvascular complications.
These findings were consistent with our hypotheses
drawn from the Piette and Kerr model theorizing that
RA (a condition whose care is discordant from routine
diabetes care) would predict less A1c testing. A1c testing
is generally perceived as a diabetes care goal but not a
RA priority, which might explain lower testing rates in
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Table 1 Characteristics of Medicare diabetes patients with and without RA (N = 256,331)
Characteristic DM + RA
(n = 5,572)
DM no RA (n = 250,759) P-value
Sociodemographics, n (%)
Age 65 to 74 years 3,056 (54.9) 136,288 (54.4) 0.47
75 to 84 years 2,124 (38.1) 95,540 (38.1) 1
85+ years 392 (7.0) 18,931 (7.6) 0.16
Female 4,164 (74.7) 151,846 (60.6) <0.01
Race/ethnicity White 4,318 (77.5) 207,565 (82.8) <0.01
Black 716 (12.9) 26,495 (10.6) <0.01
Other 538 (9.7) 16,699 (6.7) <0.01
Medicaid 1,480 (26.6) 46,944 (18.7) <0.01
RUCA category Urban 3,936 (71.8) 164,742 (66.4) <0.01
Suburban 407 (7.4) 23,007 (9.3) <0.01
Large town 554 (10.1) 31,229 (12.6) <0.01
Small town 586 (10.7) 29,033 (11.7) <0.01
Baseline cardiovascular profile, n (%)
Myocardial infarction 266 (4.8) 11,146 (4.4) 0.24
Ischemic heart disease 3,237 (58.0) 126,690 (50.5) <0.01
Congestive heart failure 2,063 (37.0) 73,057 (29.1) <0.01
Stroke/Transient ischemic attack 793 (14.2) 31,971 (12.8) <0.01
Hyperlipidemia 4,151 (74.5) 190,713 (76.1) <0.01
Baseline diabetes complication profile, n (%)
Peripheral vascular disease 2,410 (43.3) 82,440 (32.9) <0.01
Chronic kidney disease 952 (17.1) 35,984 (14.4) <0.01
Lower extremity ulcers 703 (12.6) 17,815 (7.1) <0.01
Amputation 50 (0.9) 1,587 (0.6) <0.05
Diabetic eye disease 765 (13.7) 40,417 (16.1) <0.01
Other comorbidity and baseline utilization measures
Orthopedic surgery, n (%) 1,452 (26.1) 32,121 (12.8) <0.01
Gait device, n (%) 492 (8.8) 12,768 (5.1) <0.01
HCC score, mean (SD) 1.55 (1.04) 0.82 (0.80) <0.01
Hospitalization 2004 to 2006, n (%) 3,379 (60.6) 125,168 (49.9) <0.01
Total unique providers, three-year mean (SD) 8.8 (5.7) 6.3 (4.0) <0.01
Total outpatient visits, annual mean (SD) 14.7 (9.3) 9.6 (6.7) <0.01
PCP visits, annual mean (SD) 7.0 (5.9) 5.3 (4.0) <0.01
Rheumatology visits, annual mean (SD) 2.0 (3.1) 0.1 (0.5) <0.01
Other specialty visits, annual mean (SD) 5.6 (5.8) 4.1 (4.7) <0.01
DM, Diabetes mellitus; HCC, Hierarchical Condition Categories; PCP, Primary care provider; RA, Rheumatoid arthritis; RUCA, Rural Urban Commuting Area; SD,
Standard deviation






95% CI Odds ratio 95% CI
Receipt of ≥2 A1c test
DM no RA 56.9 57.1 56.9 to 57.3 Referent
DM + RA 51.8 53.2 51.8 to 54.5 0.84 0.80 to 0.89
Receipt of ≥1 LDL test
DM no RA 76.7 76.7 76.5 to 76.8 Referent
DM + RA 75.5 77.8 76.8 to 78.8 1.08 1.01 to 1.16
*Models also adjusted for age, gender, race/ethnicity, Medicaid buy-in, RUCA code, HCC quartile, hospitalization in a three-year period, specific co-morbidities
including diabetes complications, hyperlipidemia, chronic kidney disease, CVD, orthopedic surgeries, gait device, PCP visits and total providers.
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patients who also have competing RA care needs. Lower
A1c monitoring in diabetes patients with RA is a problem
because poor glycemic control increases the same micro-
vascular complications [5,7] that were more prevalent in
patients with RA.
In contrast, diabetes patients with RA were slightly
more likely to receive LDL testing. Dual indications for
lipid testing in those with both RA and diabetes accu-
rately predicted a concordant motivation for athero-
sclerosis prevention via LDL testing, per Piette and Kerr.
Heightened LDL testing contrasts with our groups’ prior
reports of low lipid testing in RA patients [38,39], most
likely reflecting that in the present study patients were
selected for active diabetes, a disease in which lipid
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B. Adjusted Risk Ratio of LDL Testing
Figure 2 Multivariate adjusted risk ratios for diabetes testing by additional disease covariates (N=256,331). Note that the full model also
included age, gender, race/ethnicity, Medicaid buy-in, gait device use, orthopedic surgery status, HCC quartiles, hyperlipidemia, hospitalization
status, PCP vists, provider number quartile, and RUCA rurality codes.
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performance is routinely monitored and publically
reported. The trend for slightly increased lipid testing
noted here among diabetes patients with RA also may
suggest growing awareness of CVD prevention needs in
RA [8].
Prior studies report higher morbidity and mortality
among RA patients with diabetes [1,2,40], but to our
knowledge no studies have reported heightened preva-
lence of microvascular complications in patients with
comorbid diabetes and RA. We found that CVD, with
the exception of MI, was more prevalent in patients
with both diabetes and RA. The MI rate is consistent
with other RA reports [11], including a Danish study
showing similar MI rates in patients with RA, diabetes
or both [40]. The more surprising finding was increased
chronic kidney disease, lower extremity ulcers and
amputations among diabetes patients with RA. While
this was an uncontrolled observation outside of our ori-
ginal study question, further investigations to examine
RA as a microvascular disease risk seem warranted.
Strengths of this study include the use of a large,
nationally representative sample of Medicare patients
with diabetes and RA, and extensive demographic,
comorbidity and utilization data. However, a few limita-
tions should be noted. First, there is the potential for
misclassification of RA and other diagnoses using
administrative data. Previously validated algorithms of
RA and key conditions were used. Although the strictest
validation study used rheumatologist-reported RA cod-
ing [19], we adopted the convention of subsequent
authors - two or more RA codes in 24 months [20].
Sample definitions might have improved with inclusion
of pharmacy data [41], but were not feasible given local
data limitations. Results from Medicare patients may
also not be generalizable to non-Medicare populations.
Lastly, we looked specifically at a 12-month year per
guidelines, but performance may have improved with a
one-month grace period. Despite these limitations, using
this large sample of diabetes patients with and without
RA offers new insights.
In light of reduced A1c testing in patients with
comorbid RA and diabetes, and heightened microvascu-
lar and CVD risk, we urge providers to consider DM
and RA as concordant risk factors. We recommend
further research examining the interplay between RA
and other comorbidities on care quality and outcomes
for vascular-risk conditions. This research should exam-
ine more direct quality of care measures, including
appropriateness of pharmacotherapy and prospective
morbidity and mortality. Lastly, given observed lapses in
process care measures, such as A1c testing for patients
with both RA and diabetes, additional research should
investigate optimal co-management or shared disease-
management and prevention strategies among specialty
and primary care providers.
Conclusions
Presence of co-morbid RA predicted lower performance
of A1c testing among older adults with diabetes. Con-
versely, receipt of LDL testing was slightly better in
patients with RA. Gains for LDL testing might reflect
improved recognition of dual testing indications, spurred
by EULAR recommendations to perform annual CVD
risk assessment and other RA CVD-prevention recom-
mendations. Our findings support conceptualizing RA
and diabetes on a concordant risk pathway to improve
screening for complications and diabetes monitoring
performance in patients with RA. Lower rates of A1c
monitoring, in particular, may offer a target for improv-
ing the higher-than-expected rates of microvascular
complications observed in this study for RA patients
with diabetes.
Additional material
Additional file 1: Multivariate adjusted risk ratios for diabetes
testing by additional covariates (N = 256,331). Multivariate adjusted
risk ratios for diabetes testing by additional covariates, including age, sex,
race/ethnicity, baseline comorbidities, HCC quartile, hospitalization,
orthopedic surgery, annual PCP visits and lowest total provider quartile.
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